Pepinemab
- Generic Name
- Pepinemab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2097151-87-4
- Unique Ingredient Identifier
- BPZ4A29SYE
- Background
Pepinemab is under investigation in clinical trial NCT03769155 (VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma).
- Associated Conditions
- -
- Associated Therapies
- -
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 1
Completed
- Conditions
- Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT04815720
- Locations
- 🇺🇸
Highlands Oncology Group, PA - North Hills, Springdale, Arkansas, United States
🇺🇸California Cancer Associates for Research and Excellence (CCARE)-Fresno, Fresno, California, United States
🇺🇸UCSF Medical Center at Mission Bay, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath